HOME >> MEDICINE >> NEWS
6,000 Pharmaceutical Scientists Convene November 15-19 In San Francisco

ication is ineffective at high altitudes? Pharmaceutical scientists are just beginning to study the topic and have some interesting research findings.

DHEA: Fountain of Youth or Dangerous Steroid? -- DHEA, developed to treat lupus, has recently made its way into mainstream health food stores and is being marketed as a naturally occurring "Fountain of Youth." The problem: The natural drug is converted to testosterone and can have unsightly, even dangerous side effects. The latest research shows that using DHEA can lead to facial hair growth, acne and osteoporosis in women or prostate cancer in men. After testing 16 mainstream DHEA products, researchers found that only half actually met manufacturers' label claims. Since the FDA does not yet monitor "dietary supplements," consumers need to be aware of the dangers of natural drugs.

No More Needles for Insulin Dependent Diabetes Sufferers? -- Millions of diabetes sufferers must receive daily insulin injections to avoid serious, often deadly complications. But there's hope: A leading Canadian scientist has developed and patented an oral insulin medication that's now set for human trials with the Health Protection Branch (the Canadian equivalent of the FDA). Next step -- approval in the US.

Key Seminars Topics Include:

Monday, November 16
Emerging Trends in Drug Design and Development --1:30-5 p.m. Marketing of Pharmaceuticals in a Managed Health Care Environment -- 1:30-5 p.m. Acceleration of Drug Development for Life-Threatening Diseases: FDA and Industry
'"/>

Contact: Amy Miller
miller@aaps.org
703-518-8417
American Association of Pharmaceutical Scientists
27-Oct-1998


Page: 1 2 3

Related medicine news :

1. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
2. Over 6,000 Technical Presentations Will Reveal New Findings At National Chemists Meeting In Boston, August 23 - 27
3. Pharmaceutical marketing tactics hold little sway with prescribing physicians
4. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
5. Pharmaceutical Achievers
6. Pharmaceutical industry still failing health needs of less-developed countries
7. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
8. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
9. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
10. American Association of Pharmaceutical Scientists Dietary Supplements Forum examines science behind nutraceuticals
11. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pharmaceutical Scientists Convene November San Francisco

(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...
(Date:5/21/2013)... May 21, 2013 Two-thirds of patients ... cell lung cancer reported that they engage in at ... use, according to new findings from the National ... Kantar Health . The research will be presented today ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
(Date:5/21/2013)... 2013 A plastic surgery Internet ... plastic surgery SEO services following an Internet survey. ... name the “Best Plastic Surgery SEO Services”. , ... was predictable. Well-known in the plastic surgery Internet ... than any other selection based on superior client ...
(Date:5/21/2013)... May 21, 2013 It’s nearly summer and ... camp or starting practice for summer or fall sports. ... or sporting activities can begin. , To help parents ... for youth sports or camp physicals at just ... will review a child’s medical history, perform a physical exam ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: